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Abstract To delineate the clinical characteristics of neuro-
Behc ¸et’s disease (NBD), a multicenter retrospective survey
was performed in BD patients who had presented any neu-
rological manifestations between 1988 and 2008. The diag-
nosis of acute NBD, chronic progressive (CP) NBD, and
non-NBD was conﬁrmed by retrospective review of clinical
records.Dataonatotalof144patientswerecollected;76with
acute NBD, 35 with CP NBD, and 33 with non-NBD. High-
intensitylesionsonT2-weightedmagneticresonanceimaging
(MRI) were found in 60.5% of the patients with acute NBD,
54.2% with CP NBD, and 42.4% with non-NBD, whereas
brainstem atrophy was observed in 7.5% with acute NBD,
71.4% with CP NBD, and 9.0% with non-NBD. The cere-
brospinal ﬂuid (CSF) cell count was prominently elevated in
patients with acute NBD, but was normal in about 15% of
thosewithCPNBD.ThesensitivityandspeciﬁcityoftheCSF
cell count for the diagnosis of acute NBD versus non-NBD
were 97.4 and 97.0%, respectively (cut-off 6.2/mm
3). The
sensitivity and speciﬁcity of CSF interleukin (IL)-6 for the
diagnosisofCPNBDversustherecoveryphaseofacuteNBD
were86.7and94.7%,respectively(cut-off16.55 pg/ml).The
results indicate that elevation of the CSF cell count and CSF
IL-6andthepresenceofbrainstematrophyonMRIareuseful
for the diagnosis of NBD.
Keywords Behc ¸et’s disease  Central nervous system 
Cerebrospinal ﬂuid  Diagnostic criteria  Magnetic
resonance imaging
Introduction
Behc ¸et’s disease (BD) is a chronic relapsing inﬂammatory
disease of unknown etiology, presenting with recurrent aph-
thous stomatitis, uveitis, genital ulcers, and skin lesions. The
diseaseischaracterizedbyrecurrentepisodesofremissionand
exacerbationofvarioussymptoms,whereaschronicsustained
inﬂammation in certain tissues is rare [1]. Central nervous
system(CNS) involvementinBDiscausedeitherbyprimary
neural parenchymal lesions [neuro-Behc ¸et’s disease (NBD)]
or is secondary to major vascular involvement [2–4]. The
latter type should be called vasculo-BD [2]. Several recent
studies have disclosed that the parenchymal lesions (NBD)
can be classiﬁed as acute NBD and chronic progressive (CP)
NBD depending on their differential clinical courses, espe-
cially on their differential responses to steroids [3, 5–8].
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DOI 10.1007/s10165-011-0533-5Because factors other than BD can cause neurological
manifestations, the diagnosis of NBD is often difﬁcult and its
treatment is challenging. The present study was therefore
designedtodelineatetheclinicalcharacteristicsofacuteNBD
andCPNBDandtodeterminereliablediagnosticparameters.
Patients and methods
Study design
ThisstudywasperformedasaprojectbytheBehc ¸et’sDisease
Research Committee (hereafter, the Research Committee)
guided by the Ministry of Health, Labor and Welfare of the
Japanese Government in accordance with the World Medical
Association Declaration of Helsinki Ethical Principles for
MedicalResearchInvolvingHumanSubjects.Thisstudywas
approved by the ethics committees of the 6 institutions with
which each of the authors is afﬁliated. We performed an
exhaustivequestionnairesurveyonBDpatientswhohadbeen
hospitalized due to neuropsychiatric manifestations between
1988 and 2008. The contents of the questionnaire included
age, gender, HLA-B51, history of smoking, date of diagnosis
of BD (fulﬁllment of the International Study Group for BD
criteria), date and details of presentation of neuropsychiatric
manifestations, cerebrospinal ﬂuid (CSF) ﬁndings, magnetic
resonance imaging (MRI) ﬁndings, treatment and outcome,
and ﬁnal diagnosis assigned retrospectively.
Eligibility criteria
PatientshadtofulﬁllthediagnosticcriteriaoftheInternational
Study Group for BD [9] and had to present with neurological
manifestations. Data on patients eligible for the study were
collected by exhaustive checking of medical records.
Diagnosis
The original diagnosis of the neuropsychiatric manifestation,
which had been made with the aid of neurologists and radi-
ologistsateachinstitutionandrecordedontheclinicalcharts,
was checked by members of the Research Committee at each
institution by retrospective review of the entire clinical
records including those in the follow-up period until 2008.
NBD was deﬁned as neurological manifestations in the
absence of an alternative condition that better explained the
neurological manifestations. After this maneuver, the ﬁnal
diagnosisofeitherNBDorneurologicalmanifestationsdueto
causes other than BD (non-NBD) was assigned and reported
on a questionnaire form. At this stage, NBD was further
classiﬁed as acute NBD or CP NBD based on the patients’
clinical courses [3, 5–8]. Thus, acute NBD was deﬁned as
acute meningoencephalitis with or without focal lesions,
which was attenuated by corticosteroids or resolved sponta-
neously, although there might have been recurrence of the
attacks or residual permanent damage or disability without
progression[7,8].CPNBDwasdeﬁnedasintractable,slowly
progressive neurological manifestations leading to severe
disability and deterioration in spite of empirical immuno-
therapy [7, 8]. The diagnosis was reconﬁrmed by the chief
membersoftheNBDStudyGroupoftheResearchCommittee
(S.H.andM.T.)throughacarefulretrospectivereviewofthe
clinicalrecords, and was ﬁnallyapproved by all the members
of the Research Committee.
CSF interleukin 6 (IL-6)
On admission, when the patients showed active neurolog-
ical manifestations, routine CSF analysis, including cell
count, total protein, and glucose, as well as CSF IL-6
testing, was done. CSF IL-6 was measured by an enzyme-
linked immunosorbent assay (ELISA) or a bioassay using
an IL-6-dependent cell line, MH60.BSF2 [6] at each
institution without knowledge of the clinical condition of
the patients. The values of CSF IL-6 determined by ELISA
have been shown to be identical with those determined by
bioassay using MH60.BSF2 [6].
Magnetic resonance imaging
Magnetic resonance imaging (MRI) scans with T1-weighted
images, T2-weighted images, and ﬂuid attenuated inversion
recovery(FLAIR)imageswithoutcontrastenhancementwere
recordedin140ofthe144patients.JudgmentofMRIﬁndings
was performed by expert radiologists at each institution.
Detailed ﬁndings and judgments by the radiologists were
reported on a questionnaire form.
Statistical analysis
Comparison of the frequencies of various ﬁndings or param-
eters among the groups was carried out using the v
2 test or
Kruskal-Wallis test with multiple comparison, where appro-
priate.Receiveroperatingcharacteristic(ROC)curveanalysis
was used to evaluate the sensitivity and speciﬁcity of various
parameters, using the software, GraphPad Prism Version 4.0
(GraphPadSoftware,SanDiego,CA,USA).Allthestatistical
analysis was done by S.H.
Results
Summary of the review of cases in the questionnaire
A total of 159 BD patients were hospitalized due to neu-
rological manifestations during the 20-year surveillance
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123period, of whom 144 patients underwent CSF examination.
The neurological manifestations in 111 of the 144 patients
were judged to have been caused by BD (76 acute NBD
and 35 CP NBD), whereas those in 33 patients were judged
as non-NBD, including 9 with atherosclerotic cerebrovas-
cular diseases, 6 with intrinsic psychiatric disorders, 5 with
systemic metabolic disorders, 4 with peripheral neuropathy
of various causes, 3 with spinal spondylosis, 3 with epi-
lepsy, and 2 with brain tumors; there was only 1 patient
with cerebral vein thrombosis (CVT), who was classiﬁed as
non-NBD. There was some overlapping in 18 patients with
NBD. Thus, 6 patients with acute NBD had another attack
of acute NBD, 9 patients with acute NBD subsequently
developed CP NBD, so called ‘‘secondary progression’’
[5], and 3 patients with non-NBD had another episode of
non-NBD. Thus, strictly speaking, 126 patients presented
144 occasions of neurological manifestations.
As summarized in Table 1, there were no signiﬁcant dif-
ferences in age or gender distribution among the 3 groups,
although there was a tendency for male predominance in all
the3groups.TheintervalbetweenthediagnosisofBDandthe
presentation of neurological manifestations was signiﬁcantly
shorterinacuteNBDcomparedwithCPNBDandnon-NBD.
Of note, the prevalences of cigarette smoking and HLA-B51
were signiﬁcantly higher in CP NBD (P = 0.0024 and
0.0106, respectively), whereas signiﬁcantly higher numbers
of acute NBD patients had been taking cyclosporin
(P\0.0001).
Clinical neurological manifestations (Table 2)
Among a variety of neurological manifestations, headache
and fever were more common in acute NBD, whereas
ataxia, dysarthria, urinary incontinence, and neurobeha-
vioral/cognitive symptoms were more frequently observed
in CP NBD. Headache and ataxia were also commonly
observed in non-NBD. Focal neurological deﬁcit was less
frequent in CP NBD, although the difference in frequency
compared with that in acute NBD or non-NBD was not
statistically signiﬁcant. Vertigo was more frequent in acute
NBD, although it also occurred in non-NBD.
MRI ﬁndings
MRI was done in all patients, except for 4 with acute NBD,
who showed only fever and/or headache. High-intensity
lesions on FLAIR images or T2-weighted images were
observed in 60.5, 54.2, and 42.4% of patients with acute
NBD, CP NBD, and non-NBD, respectively (P = 0.1149),
indicating that these high-intensity lesions were not spe-
ciﬁc for NBD. These high-intensity lesions were most
frequently observed in the pons, midbrain, and basal gan-
glia (Table 3). By contrast, brainstem atrophy was
observed in 7.5, 71.4, and 9.0% of the patients with acute
NBD, CP NBD, and non-NBD, respectively (P\0.0001),
indicating that it was speciﬁc for CP NBD.
CSF ﬁndings
Routine CSF analysis was performed in all the 144
patients. CSF cell counts were signiﬁcantly elevated in
acute NBD compared with non-NBD and CP NBD
(Fig. 1a). CSF cell counts were also signiﬁcantly elevated
in CP NBD compared with non-NBD, but they were within
normal limits in approximately 15% of the CP NBD
patients. Signiﬁcant increases in CSF total protein, as well
as decreases in CSF glucose level, were observed in acute
NBD and CP NBD compared with non-NBD, although
most patients showed normal CSF total protein and glucose
(Fig. 1b, c).
Table 1 Demographic features
in 144 patients with Behc ¸et’s
disease (BD)
NBD Neuro-Behc ¸et’s disease
* Statistical signiﬁcance was
evaluated by the Kruskal-Wallis
test with multiple comparison
a Statistical signiﬁcance was
evaluated by the v
2 test
b One patient received
tacrolimus instead of
cyclosporin
Acute NBD
(%)
Chronic
progressive
NBD (%)
Non-NBD
(%)
P value
n 76 35 33
Age at onset of BD (years) 39.5 ± 11.8
(mean ± SD)
42.2 ± 11.4 44.6 ± 14.6 0.1578*
Interval between onset of BD and onset of
neurological symptoms (years)
5.0 ± 5.2
(mean ± SD)
8.2 ± 5.5 10.9 ± 12.0 0.0040*
Follow-up period (years) 7.9 ± 6.2
(mean ± SD)
8.9 ± 6.3 4.9 ± 4.4 0.0233*
Gender (M:F) 49:27 27:8 20:13 0.2955
a
HLA-B51 23/44 (52.3) 24/28 (85.7) 9/17 (52.9) 0.0106
a
Smoking 47/68 (69.1) 31/34 (91.2) 15/29 (51.7) 0.0024
a
Cyclosporin use
b 26/76 (34.2) 1/35 (11.1) 1/33 (3.0) \0.0001
a
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with cyclosporin and those without cyclosporin
in the acute NBD group
It is unclear and still under debate whether cyclosporin-
induced neurological manifestations might be different
from those of acute NBD. We therefore compared the
clinical characteristics of patients with cyclosporin with the
characteristics of those without cyclosporin. All the 26
patients with cyclosporin had eye involvement, whereas 43
of the 50 patients without cyclosporin also had eye
involvement. As shown in Table 4, there were no signiﬁ-
cant differences in demographic features, clinical symp-
toms, MRI ﬁndings, or laboratory ﬁndings between patients
with cyclosporin and those without cyclosporin. There
were no signiﬁcant differences in the distribution of high-
intensity lesions on MRI between the 2 groups, either (data
not shown). These results therefore suggest that cyclo-
sporin-induced neurological manifestations might be
almost identical with those of acute NBD.
ROC analysis of various parameters
The sensitivity and speciﬁcity of the CSF cell count for the
diagnosis of acute NBD versus non-NBD were 97.4 and
97.0%, respectively, at the cut-off value of 6.2/mm
3
(P\0.0001) (Fig. 2a), whereas the sensitivity and speci-
ﬁcity of the CSF cell count for the diagnosis of CP NBD
versus non-NBD were 68.6 and 97.0%, respectively, at the
cut-off value of 6.0/mm
3 (P\0.0001) (Fig. 2b).
The sensitivity and speciﬁcity of CSF IL-6 for the
diagnosis of CP NBD versus non-NBD were 96.0 and
100%, respectively, at the cut-off value of 5.5 pg/ml
(P\0.0001) (Fig. 2c). It should be noted, however, that
CP NBD often follows episodes of acute NBD [5, 6]. It is
therefore very important to discriminate CP NBD from the
recovery phase of acute NBD. ROC curve analysis was
performed for the 19 patients with acute NBD in the
recovery phase (2–8 weeks after the attacks) and for the 25
patients with CP NBD. As shown in Fig. 2d, the sensitivity
and speciﬁcity of CSF IL-6 for the differential diagnosis of
Table 2 Clinical symptoms in
144 patients with Behc ¸et’s
disease
* Statistical signiﬁcance was
evaluated by the v
2 test
Acute NBD (%) Chronic progressive
NBD (%)
Non-NBD
(%)
P value*
n 76 35 33
Headache 41 (53.9) 2 (5.7) 14 (42.4) \0.0001
Fever 43 (56.6) 1 (2.9) 3 (9.1) \0.0001
Neurobehavior/cognitive symptoms 7 (9.2) 18 (51.4) 3 (9.1) \0.0001
Alteration of consciousness 7 (9.2) 1 (2.9) 5 (15.1) 0.2088
Ataxia 9 (11.8) 17 (48.6) 10 (30.3) 0.0001
Dysarthria 14 (18.4) 15 (42.9) 3 (9.1) 0.0019
Focal symptoms (motor, sensory, etc.) 20 (26.3) 7 (20.0) 10 (30.3) 0.6136
Bladder/bowel disturbances 2 (2.6) 6 (17.1) 2 (6.1) 0.0208
Dizziness 0 2 (5.7) 4 (12.1) 0.0123
Vertigo 8 (10.5) 0 3 (9.1) 0.1429
Table 3 Location of high-intensity lesions on T2-weighted magnetic resonance imaging (MRI) scans or FLAIR images in patients with Behc ¸et’s
disease
Acute NBD (%) Chronic progressive NBD (%) Non-NBD (%) P value*
n 72
a 35 33
Cerebral white matter 12 (16.7) 5 (14.3) 8 (24.2) 0.5244
Basal ganglia 17 (9.7) 4 (11.4) 1 (3.0) 0.0194
Internal capsule 10 (13.9) 6 (17.1) 3 (9.1) 0.6214
Midbrain 18 (25.0) 4 (11.4) 2 (6.1) 0.0336
Pons 23 (31.9)
b 9 (25.7) 2 (6.1) 0.0158
Bulb 4 (5.6) 2 (5.7) 0 0.3801
Cerebellum 3 (4.2) 1 (2.9) 1 (3.0) 0.9259
FLAIR ﬂuid attenuated inversion recovery
* Statistical signiﬁcance was evaluated by the v
2 test
a MRI was not done in 4 of 76 patients with acute NBD
b Including 1 patient with hemorrhage
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and 94.7%, respectively, at the cut-off value of 16.55 pg/ml
(P\0.0001). These results indicate that CSF IL-6 was a
useful tool for the diagnosis of CP NBD in BD patients
who showed neurological manifestations of insidious
onset, whereas the CSF cell count was a sensitive and
reliable marker for the diagnosis of acute NBD in BD
patients who showed neurological manifestations of acute
or subacute onset. Because CSF IL-6 and the CSF cell
count have been found to be elevated in CNS infections, it
is necessary to rule out such conditions, especially in acute
NBD. Based on these ﬁndings, diagnostic criteria for acute
NBD and CP NBD are proposed, as shown in Table 5.
Treatment
Precise evaluation of the efﬁcacy of treatment choices is
beyond the scope of this paper. It should be noted, how-
ever, that more than 80% of the patients with acute NBD
were treated with corticosteroid, whereas approximately
75% of the patients with non-NBD received immunosup-
pressive treatment including corticosteroid. Approximately
half of the patients with CP NBD received methotrexate
(MTX) and/or corticosteroid. Only 1 patient with CP NBD
was given inﬂiximab.
Discussion
We have summarized the clinical data of BD patients who
showed neurological manifestations between 1988 and
2008. Only 1 of the 144 patients showed cerebral vein
thrombosis (CVT), and this patient was classiﬁed as having
non-NBD, conﬁrming that the incidence of CVT in BD in
Japan is much lower than that in Middle-Eastern or Euro-
pean counties [2–5]. The reason for the paucity of CVT in
BD patients in Japan remains unclear. It is suggested that
some ethnic differences in genetic factors might be
involved, as in the case of intestinal involvement, which is
much more common in the Japanese population [1].
Another possible reason for the low frequency of CVT in
our study was that our sample size was relatively small.
Further studies with a larger number of patients would be
necessary to evaluate the frequency of CVT in BD patients
in Japan.
The results in the present study have conﬁrmed that
HLA-B51 and cigarette smoking are associated with CP
NBD, as was reported previously [10]. The role of HLA-
B51 and smoking in the progression of CNS inﬂammation
might involve immune responses that need to be further
clariﬁed. On the other hand, it has been found that cyclo-
sporin is frequently associated with acute NBD, at least in
Japanese patients [11]. Consistently, in our series of
patients, 34.2% of patients with acute NBD had been tak-
ing cyclosporin (including 1 patient with tacrolimus) when
they developed neurological manifestations [11]. In con-
trast with the neurotoxicity of cyclosporin in patients
with organ transplantation, such as posterior reversible
Fig. 1 Cerebrospinal ﬂuid (CSF) in neuro-Behc ¸et’s disease (NBD).
CSF cell count (a), total protein (b), and glucose (c), in patients with
acute NBD, chronic progressive (CP) NBD, and non-NBD. Statistical
signiﬁcance was analyzed by the Kruskal-Wallis test with multiple
comparison
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123encephalopathy syndrome (PRES), the neurological mani-
festations induced by cyclosporin in the BD patients in our
series were always accompanied by an elevation of CSF
cell counts and IL-6. Of note, a previous report disclosed
that patients with cyclosporin-induced PRES showed nor-
mal CSF ﬁndings [12], suggesting that the pathogenesis of
cyclosporin-induced PRES is different from that of acute
NBD induced by cyclosporin. There were no signiﬁcant
differences in demographic features, clinical symptoms, or
laboratory ﬁndings between patients with cyclosporin and
those without cyclosporin in the acute NBD group in the
present study. It is therefore very likely that cyclosporin
might induce acute NBD. A recent report from Turkey also
conﬁrmed the association of cyclosporin with NBD [13].
Based upon the differences in clinical courses and
responses to corticosteroid treatment, NBD can be classi-
ﬁed as acute NBD or CP NBD [7, 8]. Acute NBD is
characterized by acute meningoencephalitis with or with-
out focal lesions, presenting high-intensity areas on
T2-weighted MRI scans or FLAIR images [7, 8]. Acute
NBD responds to corticosteroid therapy, and is usually
self-limiting, although recurrence of attacks is sometimes
seen [7]. By contrast, CP NBD is characterized by intrac-
table, slowly progressive neurobehavioral changes, ataxia,
and dysarthria, leading to severe disability and deteriora-
tion [6–8]. Of note, CP NBD is resistant to conventional
treatments with corticosteroid, cyclophosphamide, or aza-
thioprine [7, 14], although the efﬁcacy of low-dose weekly
MTX in CP NBD has been suggested [14]. Akman-Demir
et al. [5] proposed subsets of NBD, including attack(s) and
remission, secondary progression, primary progression, and
silent neurological involvement. Attack(s) and remission in
their series are considered to correspond to acute NBD,
whereas primary and secondary progression would be the
same as CP NBD. Similarly, Kidd et al. [3] reported 50
patients with NBD, the majority with only single attacks,
one-third with further attacks, and 4 with progressive
deterioration leading to disability. In their series of
patients, one or repeated attacks correspond to acute NBD,
and progressive deterioration would be the same as CP
NBD. Our present study has shown that the frequency of
CP NBD was 31.5% of NBD patients, a ﬁnding which was
comparable to that in the previous report of Akman-Demir
et al. [5]. Because of the different responses to treatment of
CP NBD and acute NBD, especially the response to cor-
ticosteroid, and because of differences in outcome, it is
quite important to discriminate CP NBD from acute NBD.
Headache is the most common neurological symptom
seen in BD [4, 15]. Consistently, in the present study,
headache and fever were observed in the majority of
patients with acute NBD, whereas these symptoms were
rare in patients with CP NBD. However, it should be
pointed out that headache was present in 53.9% of the
patients with acute NBD and 42.4% of the patients with
non-NBD, consistent with previous ﬁndings that headache
is also a common symptom in BD independent of neuro-
logical involvement [4, 15]. Therefore, it is difﬁcult to
delineate acute NBD versus non-NBD by the presence of
headache alone. On the other hand, ataxia, dysarthria, and
neuropsychiatric symptoms were frequently observed in
CP NBD [7]. These neuropsychiatric symptoms were
consistent with the neurobehavioral changes previously
reported by Siva et al. [4]; these changes included cogni-
tive dysfunction, euphoria, loss of insight, disinhibition,
indifference to their disease, psychomotor agitation or
retardation, and paranoid attitudes and obsessive concerns.
High-intensity lesions on FLAIR images or T2-weighted
MRI scans have been shown to be frequently observed in
Table 4 Comparison of clinical characteristics between patients with cyclosporin and those without cyclosporin in the acute NBD group
With cyclosporin (%) Without cyclosporin (%) P value*
n 26 50
Interval between onset of BD and onset of NBD (years)
a 5.5 ± 4.7 4.7 ± 5.6 0.5197
Gender (M:F) 19:7 30:20 0.3802
HLA-B51 8/15 (53.3) 15/29 (51.7) 1.0000
Smoking 16/19 (84.2) 31/49 (63.3) 0.1661
Headache 11 (42.3) 30 (60.0) 0.2204
Fever 15 (57.7) 28 (56.0) 1.0000
High-intensity lesions (FLAIR or T2) on MRI 18 (69.2) 28/46 (60.9) 0.6498
Serum CRP (mg/dl)
a 2.24 ± 3.00 4.25 ± 5.83 0.0584

CSF cell counts (/3 mm
3)
a 391.2 ± 419.2 432.9 ± 652.9 0.7366

CSF IL-6 (pg/ml)
a 442.9 ± 786.2 1035.1 ± 1072.8 0.1652

MRI magnetic resonance imaging, CRP C-reactive protein, CSF cerebrospinal ﬂuid, IL interleukin
* Statistical signiﬁcance was evaluated by the v
2 test or
by Student’s t-test
a Data are expressed as means ± SD
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123Fig. 2 Receiver operating characteristic (ROC) analysis of the CSF
cell count and CSF interleukin-6 (IL-6) for the differential diagnosis
of NBD. a, b ROC analysis of the CSF cell count for the differential
diagnosis of acute NBD and CP NBD from non-NBD. The sensitivity
and speciﬁcity of CSF cell counts for the diagnosis of acute NBD
versus non-NBD were 97.4 and 97.0%, respectively, at the cut-off
value of 6.2/mm
3 (a) [area under the curve (AUC): 0.9984 (95%
conﬁdence interval; CI, = 0.9951–1.002), P\0.0001], whereas the
sensitivity and speciﬁcity of the CSF cell count for the diagnosis of
CP NBD versus non-NBD were 68.6 and 97.0%, respectively, at the
cut-off value of 6.0/mm
3 [AUC: 0.9126 (95% CI = 0.8473–0.9778),
P\0.0001] (b). c, d ROC analysis of CSF IL-6 for the diagnosis of
CP NBD. The sensitivity and speciﬁcity of CSF IL-6 for the
differential diagnosis of CP NBD (n = 25) versus non-NBD (n = 12)
were 96.0 and 100%, respectively, at the cut-off value of 5.5 pg/ml
[AUC: 0.9767 (95% CI = 0.9292–1.024), P\0.0001] (c), whereas
the sensitivity and speciﬁcity of CSF IL-6 for the diagnosis of CP
NBD (n = 25) versus acute NBD in the recovery phase (n = 19)
were 92.0 and 94.7%, respectively, at the cut-off value of 16.55 pg/ml
[AUC: 0.9411 (95% CI = 0.8626–1.020), P\0.0001] (d)
Table 5 Proposed preliminary
diagnostic criteria for
classiﬁcation of NBD
Acute NBD
1. Fulﬁlling the International Study Group (ISD) criteria for BD
2. Acute or subacute onset of neurological symptoms, including headache, fever, or any
focal signs
3. Increase in the CSF cell count of more than 6.2/mm
3
*The diagnosis of acute NBD requires all the above items 1–3
Exclusion: infections of the central nervous system
Chronic progressive NBD
1. Fulﬁlling the ISD criteria for BD
2. Insidious onset of neuropsychiatric symptoms, including dementia/neurobehavior changes, ataxia,
and dysarthria, with or without other manifestations
3. Presence of one of the following:
a. Increase in CSF IL-6 of more than 17.0 pg/ml on 2 different occasions at intervals of at least
2 weeks
b. Increase in CSF IL-6 of more than 17.0 pg/ml and the presence of brainstem atrophy on MRI
*The diagnosis of chronic progressive NBD requires all the above items 1–3
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123NBD, especially in the brainstem-diencephalon and
pontobulbar regions [16]. In accordance with these ﬁnd-
ings, high-intensity lesions were frequently seen in the
pons, midbrain, and basal ganglia in acute NBD as well as
CP NBD in the present study. However, there were no
signiﬁcant differences in the frequencies of FLAIR or
T2-weighted high-intensity lesions among acute NBD,
CP NBD, and non-NBD. These high-intensity lesions
were observed in as many as 42.4% of our non-NBD
patients, but in as few as 54.2% of the acute NBD
patients. Therefore, it is evident that the inclusion of
abnormal MRI ﬁndings in the diagnostic criteria of acute
NBD results in reduced sensitivity and speciﬁcity. By
contrast, brainstem atrophy was observed signiﬁcantly
more frequently in CP NBD (71.4%) than in acute NBD
(7.5%) or non-NBD (9.0%), indicating that brainstem
atrophy is a frequent and speciﬁc ﬁnding in CP NBD and
therefore can be included in the diagnostic criteria.
Determination of the presence of brainstem atrophy in the
present study depended on the anecdotal judgment of
expert radiologists, and thus, a more objective deﬁnition
of brainstem atrophy could be required.
The efﬁcacy of CSF analysis in the diagnosis of NBD
h a sb e e np o o r l ye x p l o r e di nt h el i t e r a t u r e[ 3, 5]. In a study
with a limited number of patients, CSF constituents were
shown to be altered in only around 70–80% of patients
with parenchymal NBD [17]. In fact, in the present study,
elevation of the CSF cell count was not observed in 9 of
35 patients with CP NBD. However, almost all of the 76
patients with acute NBD showed elevation of the CSF
cell count, whereas the CSF cell count was within normal
ranges in all the 33 patients with non-NBD. Thus, the
sensitivity and speciﬁcity of the CSF cell count for the
diagnosis of acute NBD versus non-NBD were as high
as 97.4 and 97.0%, respectively, at the cut-off value of
6.2/mm
3, providing strong evidence for the rationale
of inclusion of the CSF cell count in the proposed diag-
nostic criteria for acute NBD; however, the sensitivity
of CSF cell counts for the diagnosis of CP NBD was
unsatisfactory.
It should be pointed out that infectious meningoen-
cephalitis is accompanied by an elevation of the CSF cell
count. Therefore, it is mandatory to exclude the possi-
bility of infectious meningoencephalitis in the diagnosis
of acute NBD (Table 5). In addition, multiple sclerosis
might show similar lesions, including those of the
brainstem, along with an elevation of the CSF cell count.
However, it has been very rare that multiple sclerosis
occurs in patients who have fulﬁlled the diagnostic cri-
teria of BD, although careful differential diagnosis from
acute NBD is important.
Recently, increasing attention has been paid to CSF
cytokines, especially IL-6, in NBD. Thus, CSF IL-6 has
been shown to be increased in patients with relapsing-
remitting NBD (acute NBD), as well as in those with
progressive NBD (CP NBD) [6, 18–21]. Consistently, in
the present study, CSF IL-6 was elevated in acute NBD as
well as in CP NBD, but not in non-NBD. Previous studies
demonstrated that CSF IL-6 was not elevated in patients
with multiple sclerosis [22, 23]. Therefore, the determi-
nation of CSF IL-6 might be useful for the differential
diagnosis of NBD and multiple sclerosis. CSF IL-6 has
been found to be decreased after successful treatment of
acute NBD [19]. It should be noted that a number of
patients with CP NBD have a preceding history of attacks
of acute NBD [6, 7]. It is therefore possible that those
patients with acute NBD whose CSF IL-6 levels do not
return to normal ranges might develop CP NBD. It is thus
important to discriminate patients with acute NBD who
continue to have persistent inﬂammation leading to CP
NBD from those who completely recover from acute
NBD without further progression. In this regard, we have
demonstrated that the sensitivity and speciﬁcity of CSF
IL-6 for the differential diagnosis of CP NBD from
non-progressive acute NBD in the recovery phase were
92.0 and 94.7%, respectively, at the cut-off value of
16.55 pg/ml.
We previously disclosed that patients with CP NBD
presented with persistent marked elevation of CSF IL-6
([20 pg/ml), lasting more than 3 months, with a modest
increase in CSF cell numbers and total protein [6]. It is
therefore essential to show this sustained elevation of IL-6
for the diagnosis of CP NBD, requiring the examination of
CSF IL-6 on at least 2 occasions. Because most patients
with acute NBD showed lower levels of CSF IL-6
2–8 weeks after the initial diagnosis than those with CP
NBD, the interval of time between the two occasions of
CSF IL-6 examination might well be at least 2 weeks,
although further studies are required to determine the
precise interval. Alternatively, brainstem atrophy, which
was found to be speciﬁc for CP NBD, might be a result of
prolonged inﬂammation. Therefore, its presence with ele-
vation of CSF IL-6 on a single occasion is considered to
provide strong evidence for CP NBD.
In summary, the results in the present multicenter ret-
rospective study have disclosed the characteristic features
of acute NBD as well as those of CP NBD, leading to the
proposed diagnostic criteria for each. It should be pointed
out that CSF IL-6 was examined in only 40% of patients in
the present study. Because the sample size of the present
study was relatively small, the paucity of CSF IL-6 data
might be a limitation of our study results. Accumulating
data on CSF IL-6 would be needed to conﬁrm the results of
our study. In this regard, a prospective study for validation
of the preliminary diagnostic criteria, especially those for
CP NBD, would be very important.
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